Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Mehr anzeigen
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a...
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.044 | 5.85885486019 | 0.751 | 0.8709 | 0.7366 | 44275 | 0.79973897 | CS |
| 4 | -0.135 | -14.5161290323 | 0.93 | 1 | 0.61 | 68883 | 0.86155302 | CS |
| 12 | -0.175 | -18.0412371134 | 0.97 | 1.44 | 0.61 | 1238584 | 1.17095535 | CS |
| 26 | -1.085 | -57.7127659574 | 1.88 | 4.55 | 0.61 | 1260199 | 2.01376327 | CS |
| 52 | -8.249 | -91.2096417514 | 9.044 | 12.36598 | 0.61 | 1028149 | 2.95603599 | CS |
| 156 | -84.205 | -99.0647058824 | 85 | 105.6 | 0.61 | 621002 | 9.62086935 | CS |
| 260 | -143.205 | -99.4479166667 | 144 | 486.8 | 0.61 | 640563 | 70.30813511 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
